LEISH-F3 + GLA-SE
LEISH-F3 + GLA-SE is the name of first vaccine, which was sent on trials against Kala-Azar in India and US recently. Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research body has launched the trials of the first ever vaccine in India and US to prevent kala azar, or visceral leishmaniasis (VL). The project is funded by Bill & Melinda Gates Foundation. The IDRI vaccine, known as LEISH-F3 + GLA-SE, is a highly purified, recombinant vaccine. It incorporates two fused Leishmania parasite proteins and a powerful adjuvant to stimulate an immune response against the parasite.